Boston, MA -- (SBWIRE) -- 06/24/2016 -- Global Markets Direct's, 'Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016', provides in depth analysis on Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted pipeline therapeutics.

The report provides comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics development and features dormant and discontinued projects.

Get More Details on this Report and a Full Table of Contents at Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Report Scope

-The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1)
-The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics and enlists all their major and minor projects
-The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted therapeutics

Reasons to Get this Report

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned in this Report: AdAlta Pty Ltd., Bristol-Myers Squibb Company, Epigen Biosciences, Inc., F. Hoffmann-La Roche Ltd., Ono Pharmaceutical Co., Ltd., RxBio, Inc., Sanofi

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016
-Nuclear Receptor ROR-Gamma (Nuclear Receptor RZR-Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR-Related Orphan Receptor C or Retinoid-Related Orphan Receptor-Gamma or RORC) - Pipeline Review, H1 2016
-KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Review, H1 2016
-Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016
-Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Pipeline Review, H1 2016